drugset
drugset / Trial / NCT04387448

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

NCT04387448 ↗

Phase 2 Terminated 96 enrolled Goldfinch Bio, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD).

Timeline

Start
2020-07-28
Primary completion
2022-11-01
Completion
2022-11-01

Outcome

Outcome not reported

Stopped (Business): “Business reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject GFB-887 Small molecule — —

Indications

diabetes mellitus diabetic kidney disease focal segmental glomerulosclerosis minimal change disease nephrosis